Carregant...
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache
BACKGROUND: Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repe...
Guardat en:
| Publicat a: | Cephalalgia |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7412872/ https://ncbi.nlm.nih.gov/pubmed/32615788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102420938652 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|